Antisense-induced exon exclusion in type VII collagen

Inventors

Mourich, Dan V.

Assignees

Sarepta Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11911403-B2

Patent

Publication Date

2024-02-27

Expiration Date


Abstract

The present disclosure relates to antisense oligomers and related compositions and methods for increasing the expression of functional human type VII collagen and methods for treating dystrophic epidermolysis bullosa and related disorders and relates to inducing exclusion of exon 80 in human type VII collagen mRNA.

Core Innovation

The disclosure relates to antisense oligomer compounds for human type VII collagen pre-mRNA. The antisense oligomer comprises 12 to 40 subunits and includes at least one nucleotide analog subunit having a modified internucleoside linkage, a modified sugar moiety, or a combination of the foregoing. A targeting sequence complementary to 12 or more contiguous nucleotides in a target region spanning an exon/intron junction of human type VII collagen pre-mRNA is specified, including the splice junction of exon 80/intron 80.

The targeting sequence is selected from SEQ ID NOS: 27, 28, 29, and 30, including fragments and variants with ≥90% identity. The disclosure also provides allowable compound structures using general chemical formulas and defines relationships of sequence targeting in terms of complementarity and identity requirements in the context of splice modulation. Additional embodiments include phosphorothioate, phosphoramidate, and phosphorodiamidate internucleoside linkages, as well as optional conjugation to an arginine-rich cell-penetrating peptide at the 3′ or 5′ end of the antisense oligomer.

The antisense oligomer is directed to increase expression or accumulation of functional type VII collagen by inducing exon 80 skipping at the exon 80/intron 80 splice junction. The disclosure further includes pharmaceutical composition embodiments and describes in vitro functional data showing improved exon 80 skipping of human type VII collagen pre-mRNA for specific antisense oligomers targeting the exon 80/intron 80 splice junction.

Claims Coverage

The combined set includes three independent claim features centered on an antisense oligomer of 12 to 40 subunits directed to the exon 80/intron 80 splice junction in human type VII collagen pre-mRNA, with specified SEQ ID NOs; one claim additionally requires nucleotide-analog structure.

12-to-40 subunit antisense oligomer with nucleotide-analog subunit

An antisense oligomer compound of 12 to 40 subunits comprising at least one subunit that is a nucleotide analog having a modified internucleoside linkage, a modified sugar moiety, or a combination of the foregoing.

Targeting sequence spanning exon 80/intron 80 splice junction

A targeting sequence complementary to 12 or more contiguous nucleotides in a target region spanning an exon/intron junction of human type VII collagen pre-mRNA, wherein the exon/intron junction comprises the splice junction of exon 80/intron 80, and the targeting sequence is selected from SEQ ID NOS: 27, 28, 29, and 30.

Specific sequence that specifically hybridizes to exon 80/intron 80 splice junction

An antisense oligomer compound comprising a sequence of 12 to 40 subunits that specifically hybridizes to a target region spanning an exon/intron junction of human type VII collagen pre-mRNA, said exon/intron junction comprising the splice junction of exon 80/intron 80, wherein the sequence is selected from SEQ ID NOS: 27, 28, 29 or 30.

Arginine-rich cell-penetrating peptide conjugation

A composition comprising the antisense oligomer further includes an arginine-rich cell-penetrating peptide conjugated to either the 3′ or the 5′ end of the antisense oligomer.

Pharmaceutical composition containing the antisense oligomer

A pharmaceutical composition that includes an antisense oligomer compound as defined in the independent claim.

The claims are directed to antisense oligomers of 12 to 40 subunits that target and specifically hybridize at the exon 80/intron 80 splice junction of human type VII collagen pre-mRNA, with specified SEQ ID selection; one independent claim additionally requires nucleotide-analog subunits having modified internucleoside linkages and/or modified sugar moieties.

Stated Advantages

Improved exon 80 skipping of human type VII collagen pre-mRNA for specific antisense oligomers targeting the exon 80/intron 80 splice junction.

Increase expression or accumulation of functional type VII collagen by inducing exon 80 skipping at the exon 80/intron 80 splice junction.

Documented Applications

In vitro functional data showing improved exon 80 skipping of human type VII collagen pre-mRNA using antisense oligomers targeting the exon 80/intron 80 splice junction.

Use in relation to dystrophic epidermolysis bullosa (DEB).

Treating dystrophic epidermolysis bullosa (DEB), including RDEB, DDEB, and Hallopeau-Siemens.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.